Literature DB >> 16082221

ATM-mediated phosphorylations inhibit Mdmx/Mdm2 stabilization by HAUSP in favor of p53 activation.

Erik Meulmeester1, Yaron Pereg, Yosef Shiloh, Aart G Jochemsen.   

Abstract

The p53 tumor suppressor protein has a major role in protecting genome integrity. Under normal circumstances Mdmx and Mdm2 control the activity of p53. Both proteins inhibit the transcriptional regulation by p53, while Mdm2 also functions as an E3 ubiquitin ligase to target both p53 and Mdmx for proteasomal degradation. HAUSP counteracts the destabilizing effect of Mdm2 by direct deubiquitination of p53. Subsequently, HAUSP was shown to deubiquitinate Mdm2 and Mdmx, thereby stabilizing these proteins. The ATM protein kinase is a key regulator of the p53 pathway in response to double strand breaks (DSBs) in the DNA. ATM fine-tunes p53's response to DNA damage by directly phosphorylating it, by regulating additional post-translational modifications of this protein, and by affecting two p53 regulators: Mdm2 and Mdmx. ATM directly and indirectly induces Mdm2 and Mdmx phosphorylation, resulting in decreased activity and stability of these proteins. We recently provided a mechanism for the reduced stability of Mdm2 and Mdmx by showing that ATM-dependent phosphorylation lowers their affinity for the deubiquitinating enzyme HAUSP. Altogether, the emerging picture portrays an elaborate, but fine-tuned, ATM-mediated control of p53 activation and stabilization following DNA damage. Further insight into the mechanism by which ATM switches the interactions between HAUSP, Mdmx, Mdm2 and p53, to favor p53 activation may offer new tools for therapeutic intervention in the p53 pathway for cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16082221     DOI: 10.4161/cc.4.9.1981

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  54 in total

Review 1.  Emerging role of Lys-63 ubiquitination in protein kinase and phosphatase activation and cancer development.

Authors:  W-L Yang; X Zhang; H-K Lin
Journal:  Oncogene       Date:  2010-06-07       Impact factor: 9.867

2.  Phospho-ΔNp63α/miR-885-3p axis in tumor cell life and cell death upon cisplatin exposure.

Authors:  Yiping Huang; Alice Y Chuang; Edward A Ratovitski
Journal:  Cell Cycle       Date:  2011-11-15       Impact factor: 4.534

3.  IFI27, a novel epidermal growth factor-stabilized protein, is functionally involved in proliferation and cell cycling of human epidermal keratinocytes.

Authors:  W-L Hsieh; Y-H Huang; T-M Wang; Y-C Ming; C-N Tsai; J-H S Pang
Journal:  Cell Prolif       Date:  2015-02-09       Impact factor: 6.831

4.  Herpes simplex virus type 1 ICP0 phosphorylation mutants impair the E3 ubiquitin ligase activity of ICP0 in a cell type-dependent manner.

Authors:  Chris Boutell; Roger Everett; Joshua Hilliard; Priscilla Schaffer; Anne Orr; David Davido
Journal:  J Virol       Date:  2008-08-20       Impact factor: 5.103

Review 5.  DUBs at a glance.

Authors:  Keith D Wilkinson
Journal:  J Cell Sci       Date:  2009-07-15       Impact factor: 5.285

6.  p53 and the PWWP domain containing effector proteins in chromatin damage repair.

Authors:  Jing Hu; Yanming Wang
Journal:  Cell Dev Biol       Date:  2013-05-10

Review 7.  The predator becomes the prey: regulating the ubiquitin system by ubiquitylation and degradation.

Authors:  Allan M Weissman; Nitzan Shabek; Aaron Ciechanover
Journal:  Nat Rev Mol Cell Biol       Date:  2011-08-23       Impact factor: 94.444

8.  Mechanism of p53 stabilization by ATM after DNA damage.

Authors:  Qian Cheng; Jiandong Chen
Journal:  Cell Cycle       Date:  2010-02-01       Impact factor: 4.534

Review 9.  ATM-NF-kappaB connection as a target for tumor radiosensitization.

Authors:  Kazi Mokim Ahmed; Jian Jian Li
Journal:  Curr Cancer Drug Targets       Date:  2007-06       Impact factor: 3.428

10.  MDM4 (MDMX) and its Transcript Variants.

Authors:  F Mancini; G Di Conza; F Moretti
Journal:  Curr Genomics       Date:  2009-03       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.